MSCs have many fascinating properties, including strong immunomodulatory effects, the ability to repair damaged tissues, and the capacity in vitro to differentiate into other cells types. These traits, combined with their easy availability from different sources, has prompted researchers to look at MSCs as promising raw materials for use in cell therapy, gene therapy, and tissue engineering, the three pillars of regenerative medicine. The cumulative efforts of scientists, researchers and life science companies have resulted in the approval of 12 MSC-based cell therapies (several of which have been approved in multiple regions) and 19 MSC-based bone matrices. [Read more…]
The Emerging Role of Regenerative Treatments in Diabetic Wound Care
Diabetes is a condition that affects millions worldwide, and one of its most challenging complications is the development of chronic wounds, including skin wounds and ulcers. These persistent wounds are not only painful and debilitating but also pose significant risks for infection and amputation. Traditional treatments often fall short, leading to the exploration of advanced regenerative therapies, including stem cells and exosomes, which have the potential to transform the management of these difficult conditions.
Companies are making significant strides in this field, and clinical trials are underway to test the effectiveness of these innovative approaches. [Read more…]
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells
GERMANTOWN, MD, September 17, 2025 – uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powered by proprietary RNA-LNP technology. The kit is designed and proven to deliver best-in-class performance to reprogram peripheral blood mononuclear cells (PBMCs) to induced pluripotent stem cell (iPSC). [Read more…]
CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank
CytoMed Therapeutics Seeks to Advance Cord Blood-Derived Therapies For Auto-immune Diseases and Cancers
Long-term intention is to spin off LongevityBank as standalone biotech, offering immune cell banking and scalable NK/T cell platforms.
SINGAPORE, Aug. 28, 2025 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units that have been cryopreserved for more than a decade. This sets the impetus for establishing a new business platform to generate additional revenue streams and future growth. [Read more…]
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip
Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials
Mytos’ iDEM platform replaces traditional iPSC manufacturing with a closed, automated system that delivers consistent, GMP-ready cells while reducing cost, variability, and time to clinic
Collaborations highlight the versatility of Mytos’ iDEM platform across diverse cell types and clinical applications from blindness and hearing loss to complex bone regeneration
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 339
- Next Page »